OmniCAR is working in our hands...The questions of whether it can do what it claims on the label have been answered...First time around too, a lot of world firsts in that OmniCAR in vitro trial.
OmniCAR stands to open up Car-T market exponentially with our obedient and controllable platform...Car-T is usually reserved for the patients with days or weeks to live due to the un-controllable and potentially toxic nature of currrent Car-T therapies...OmniCAR will give clinicians the control to confidently open this next generation of Car-T to patients at a much earlier stage in their treatment..So a $5 billion per annum market could be a $50 billion market as a complete hypothetical.
OmniCAR can go after solid tumors that current Car-T can't...Due to the nature of most solid tumors having multiple proteins, conventional car-t could hypothetically need 20 different infusions of cells to target a particular cancer over an extended time by which the patient is likely dead from either the therapy or the cancer...With OmniCAR we can administer as many tags as needed to target the different proteins...OmniCAR proved it can simultaneously kill multiple/different cancer cells at once and the sky is possibly the limit to just how many at once we can go after. OmniCAR unlike conventional car-t won't become exhausted, we can metronomically stimulate our cells the way nature intended so they can continue to attack solid tumors in bursts and break them right down rather than tire out in a short few days or weeks before becoming ineffective, this makes us a much more financially viable option too,
Company market cap has exploded under Stevens tenure as managing director.
PTX-200 data was held up by covid in Florida, recruiting process was slower than expected but hoping to get the full data needed to announce before end of year, that's the hope.
In next 12 months Steven hopes.....
To announce data from a number more of OmniCAR trials
To have some big news for both ptx-100 & ptx-200
To have well and truly announced the details surrounding our secret 'Cell enhancement therapy program' at the Peter Mac...Patents are currently lodged and the data is magnificent...We know the patents were lodged about 3 months ago from public records on memory so can't be far off a provisional approval and announcement.
What keeps Steven up at night?
It use to be whether OmniCAR would work in our hands but that's been well and truly put to bed...Now it's timelines that keep him up and he and the team , both in-house and externally are working at a vicious pace to bring all these key milestones to shareholders and patients ASAP.
I actually bought up more PTX this week like many, it's simply a stock I can't get enough of and I sleep like a baby holding a sizable amount.
We have 6 different company makers in the works and diversification is the key to success in this day and age, any of these projects can make us a multi-billion dollar company and they are all very economical to run concurrently as the books reflect. If one projects falls over for whatever reason PTX has life jackets, flare guns, a whistle and a epirb to keep us safe. If ptx-100 or ptx-200 doesn't make it to market the sp pain would likely only be momentarily lived and we would still have 5 more big shots on goal.
Steven expects 2022 to be a huge year for PTX, company making.
